<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0; text-align:center;">AP5Z1 / SPG48</th></tr>
<tr><td><b>Full Name</b></td><td>AP-5 Complex Subunit Zeta 1</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>7p22.1</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[84069](https://www.ncbi.nlm.nih.gov/gene/84069)</td></tr>
<tr><td><b>OMIM</b></td><td>[613653](https://www.omim.org/entry/613653)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9D7B6](https://www.uniprot.org/uniprotkb/Q9D7B6/entry)</td></tr>
<tr><td><b>Protein Class</b></td><td>Adaptor protein complex subunit</td></tr>
<tr><td><b>Expression</b></td><td>Ubiquitous, high in brain</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
The SPG48 gene (officially designated AP5Z1) encodes the zeta subunit of the AP-5 (Adaptor Protein Complex 5) complex. This complex is a member of the adaptor protein (AP) family involved in intracellular vesicle trafficking, particularly in the endolysosomal system. Mutations in AP5Z1 cause hereditary spastic paraplegia type 48 (SPG48), a neurodegenerative disorder characterized by progressive lower limb spasticity and weakness[@slabicki2010].
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0; text-align:center;">AP5Z1 / SPG48</th></tr>
<tr><td><b>Full Name</b></td><td>AP-5 Complex Subunit Zeta 1</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>7p22.1</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[84069](https://www.ncbi.nlm.nih.gov/gene/84069)</td></tr>
<tr><td><b>OMIM</b></td><td>[613653](https://www.omim.org/entry/613653)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9D7B6](https://www.uniprot.org/uniprotkb/Q9D7B6/entry)</td></tr>
<tr><td><b>Protein Class</b></td><td>Adaptor protein complex subunit</td></tr>
<tr><td><b>Expression</b></td><td>Ubiquitous, high in brain</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
The SPG48 gene (officially designated AP5Z1) encodes the zeta subunit of the AP-5 (Adaptor Protein Complex 5) complex. This complex is a member of the adaptor protein (AP) family involved in intracellular vesicle trafficking, particularly in the endolysosomal system. Mutations in AP5Z1 cause hereditary spastic paraplegia type 48 (SPG48), a neurodegenerative disorder characterized by progressive lower limb spasticity and weakness[@slabicki2010].
The AP-5 complex plays a critical role in trafficking proteins between the trans-Golgi network, endosomes, and lysosomes. This function is essential for maintaining neuronal health, as defects in endolysosomal trafficking are implicated in multiple neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and various forms of dementia[@zavodszky2020].
The AP-5 complex is a heterotetrameric adaptor protein composed of five subunits:
Each subunit has distinct functional domains that contribute to cargo recognition, membrane association, and clathrin coat formation[@saks2011].
The AP5Z1 subunit contains several important structural elements:
AP5Z1 and the AP-5 complex localize primarily to:
The AP-5 complex functions in retrieving proteins from endosomes back to the trans-Golgi network. This retrieval pathway, often called the "retromer-independent" pathway, is essential for:
AP-5 works in coordination with several other trafficking pathways:
Proper AP-5 function is critical for lysosomal activity. Lysosomes are the primary degradative organelles in cells, and their dysfunction is a hallmark of many neurodegenerative diseases. AP-5 deficiency leads to:
SPG48 (also known as AP5Z1-related hereditary spastic paraplegia) is inherited in an autosomal recessive manner. The disease is characterized by:
The mechanisms by which AP5Z1 mutations cause HSP include:
Multiple lines of evidence connect AP-5 dysfunction to [Alzheimer's disease](/diseases/alzheimers-disease):
Studies have shown that AP5Z1 expression is altered in AD brain tissue, and that AP-5 complex components colocalize with tau pathology in affected neurons[@mazz2022].
In [Parkinson's disease](/diseases/parkinsons-disease), endolysosomal dysfunction is a prominent feature:
AP-5 and related trafficking genes have been implicated in PD risk, suggesting a broader role for endolysosomal trafficking in disease pathogenesis[@freme2021].
AP5Z1 is expressed in most human tissues, with particularly high levels in:
AP5Z1 interacts with multiple components of the trafficking machinery:
Bioinformatic analysis reveals genetic interactions with:
Given the central role of endolysosomal dysfunction in neurodegeneration, several approaches are being explored:
Key challenges in developing AP5Z1-targeted therapies include:
Słabicki et al. performed a genome-wide RNAi screen for DNA repair genes that, when knocked down, cause neurodegeneration. This screen identified AP5Z1 (then called SPG48) as a novel dementia gene, establishing a connection between the AP-5 complex and neuronal survival[@slabicki2010].
Subsequent studies characterized the clinical phenotype of AP5Z1 mutations. Harshman et al. demonstrated that AP5Z1 is the zeta-1 subunit of the AP-5 complex, and that mutations cause a recessive form of hereditary spastic paraplegia with peripheral neuropathy[@harshman2013]. Testa et al. provided detailed clinical descriptions of affected individuals[@testa2016].
Recent research has focused on understanding how AP-5 deficiency leads to neurodegeneration. Marshall et al. reviewed the role of AP-5 in intracellular trafficking and neurodegeneration[@marshall2017]. Studies have demonstrated that AP-5 deficiency leads to lysosomal dysfunction, impaired autophagy, and accumulation of protein aggregates[@renzel2019].
Ap5z1 knockout mice show embryonic lethality or severe developmental defects, demonstrating the essential nature of this gene. Tissue-specific knockouts have revealed that AP-5 is required for:
Zebrafish models of AP5Z1 deficiency show motor neuron degeneration and swimming defects, providing a tractable system for drug screening.
Key questions remaining about AP5Z1 include:
Answering these questions will require a combination of genetic, biochemical, and physiological studies in model systems and human tissue[@klingenstein2023].